All animal procedures were approved by the Centers for Disease Control and Prevention (CDC) Institutional Animal Care and Use Committee. Macaques were housed at CDC under the care of CDC veterinarians in accordance with the Guide for the Care and Use of Laboratory Animals. All procedures were performed under anesthesia and all efforts were made to minimize discomfort including providing appropriate housing conditions, dietary supplements and ample enrichment opportunities.
Female rhesus macaques received subcutaneous injections of CAB ISFI (500 mg/mL) at two different locations in the upper back (0.5–1 mL per site). Briefly, anesthetized animals were placed in ventral recumbency position and the semi-aqueous ISFI suspension loaded in a 3 cc syringe was administered in the subcutaneous space using a 16 G needle. Digital pressure was briefly applied over the administration site after the needle was removed.
To assess the feasibility of implant removal and to measure the drug tail, ISFIs that remained palpable were surgically retrieved from two macaques at week 12 (RA-1097 and RA-1093; 2 implants each) and from one animal at week 14 (RH-42012; 1 implant recovered). Animals were placed in ventral recumbency and the implant locations were confirmed through digital palpation. A surgical scalpel was used to make a single dermal incision (~1 in.) over each implant. The ISFI material was carefully separated from surrounding connective tissue and recovered mostly intact using tweezers. The incision site was visually inspected for abnormalities and subsequently flushed with sterile saline prior to being closed with Polydioxanone Sutures. Animals were monitored weekly by attending vets to assess surgical sites for proper wound healing and to ensure no signs of local infection.
Female rhesus macaques received subcutaneous injections of CAB ISFI (500 mg/mL) at two different locations in the upper back (0.5–1 mL per site). Briefly, anesthetized animals were placed in ventral recumbency position and the semi-aqueous ISFI suspension loaded in a 3 cc syringe was administered in the subcutaneous space using a 16 G needle. Digital pressure was briefly applied over the administration site after the needle was removed.
To assess the feasibility of implant removal and to measure the drug tail, ISFIs that remained palpable were surgically retrieved from two macaques at week 12 (RA-1097 and RA-1093; 2 implants each) and from one animal at week 14 (RH-42012; 1 implant recovered). Animals were placed in ventral recumbency and the implant locations were confirmed through digital palpation. A surgical scalpel was used to make a single dermal incision (~1 in.) over each implant. The ISFI material was carefully separated from surrounding connective tissue and recovered mostly intact using tweezers. The incision site was visually inspected for abnormalities and subsequently flushed with sterile saline prior to being closed with Polydioxanone Sutures. Animals were monitored weekly by attending vets to assess surgical sites for proper wound healing and to ensure no signs of local infection.
Free full text: Click here
